Clinical trials: Esophageal Cancer Metastatic
Colorectal Cancer, Esophageal Cancer
LMB-9 Immunotoxin in Treating Patients With Advanced Pancreatic, Esophageal, Stomach, Colon, or Rectal Cancer
RATIONALE: LMB-9 immunotoxin can locate tumor cells and kill them without harming normal cells. This may be an effective treatment for advanced pancreatic, esophageal, stomach, colon or rectal cancer.
- Conditions
- Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer
- Trial name
- NCT00010270
- Testing
- LMB-9 immunotoxin
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- University Hospital Freiburg
Metastatic Colorectal Cancer, Triple Negative Breast Cancer
Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors
To determine the efficacy (as measured by overall tumour response rate) of the combination of durvalumab and tremelimumab when given to previously treated patients with solid tumors harboring a high mutational load.
- Conditions
- Metastatic Colorectal Cancer, Triple Negative Breast Cancer, Prostate Adenocarcinoma, Stomach Adenocarcinoma
- Trial name
- MATILDA (NCT03982173)
- Testing
- Tremelimumab, Durvalumab
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
SBRT Combined With AK104 to Treatment Relapsed or Metastatic ESCC
The entire treatment process is divided into two phases: Phase I SBRT combined with PD-1/CTLA-4 bispecific antibody (AK104) and Phase II AK104 single-agent maintenance therapy.
- Trial name
- NCT05732662
- Testing
- SBRT, Cadonilimab
- Volunteers
- 25 people
- Sponsor
- The First People's Hospital of Changzhou
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer
This phase 2 trial evaluates the benefit of epacadostat plus pembrolizumab in combination to treat patients with gastroesophageal junction or gastric cancer that has spread to other parts of the body and cannot be removed by…
- Conditions
- Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma
- Trial name
- NCT03196232
- Testing
- Epacadostat, Pembrolizumab
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- George Albert Fisher
Cancer
Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00904514
- Testing
- gene expression analysis, microarray analysis, mutation analysis
- Volunteers
- 241 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Esophageal Cancer, Gastric Cancer
Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer
The purpose of this study is to find out what effects, good and/or bad, pembrolizumab in combination with trastuzumab and chemotherapy, has on the patients' esophagogastric cancer.
- Trial name
- NCT02954536
- Testing
- pembrolizumab, trastuzumab, capecitabine
- Where
- 8 sites in United States
- Volunteers
- 37 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Esophageal Cancer, Gastric Cancer
Edotecarin and Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as edotecarin and cisplatin, use different ways to stop tumor cells from dividing so they stop growing or die. Combining edotecarin with cisplatin may kill more tumor cells.
- Conditions
- Esophageal Cancer, Gastric Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00072332
- Testing
- cisplatin, edotecarin
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Esophageal Cancer, Gastric Cancer
Matuzumab Treatment With Epirubicin, Cisplatin and Capecitabine (ECX) in Esophago-Gastric Cancer
The purpose of this study is to compare the effectiveness and safety of experimental treatment matuzumab and ECX chemotherapy, with ECX chemotherapy.
- Trial name
- MATRIX EG (NCT00215644)
- Testing
- Matuzumab, Epirubicin, Cisplatin
- Where
- 22 sites in Germany, Spain and 2 more
- Volunteers
- 72 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Metastatic Esophageal Squamous Cell Carcinoma
Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer
This is an investigator-initiated, single-arm, exploratory clinical study.The study population consisted of treatment naive advanced esophageal squamous cell carcinoma patients.
- Trial name
- NCT06138028
- Testing
- TP regimen (cis-platinum ; Tocetaxel ) combined with PD-1 inhibitors（Sintilimab）
- Where
- 2 sites in China
- Volunteers
- 90 people
- Sponsor
- Qingdao Central Hospital
Esophageal Cancer, Gastric Cancer (GC)
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
This is a multi-site, open-label, non-randomized, single dose study to assess the clinical utility of [¹⁸F]FAPI-74 PET/CT in the detection of metastatic disease in individuals with pathologically confirmed gastric…
- Conditions
- Esophageal Cancer, Gastric Cancer (GC), Gastroesophageal Junction
- Trial name
- FAPI-GO (NCT07217704)
- Testing
- [18F]FAPI-74 PET/CT
- Where
- 19 sites in United States
- Volunteers
- 200 people
- Sponsor
- SOFIE
Esophageal Cancer
Paclitaxel Liposome and Cisplatin as First-line Chemotherapy in Patients With Metastatic Esophageal Cancer
There are no standard chemotherapy regimens for metastatic esophageal cancer. Cisplatin plus 5-fluorouracil is widely used as first-line treatment with a response rate ranged from 30% to 40%.
- Trial name
- NCT01998347
- Testing
- Paclitaxel liposome, Cisplatin, 5-fluorouracil
- Where
- China
- Sponsor
- Shantou University Medical College
Esophagus Cancer
Clinical Trial of Qizhu Yuling Prescription in the Prevention and Treatment of Esophagus Cancer
The purpose of this study is to evaluate the efficacy and safety of Qizhu Yuling prescription for postoperative esophagus cancer.
- Trial name
- NCT05626309
- Testing
- Qizhu Yuling Prescription
- Where
- 3 sites in China
- Volunteers
- 310 people
- Sponsor
- Jie Li
Esophageal Cancer, Gastric Cancer
Docetaxel and Capecitabine in Treating Patients With Metastatic Cancer of the Stomach or Gastroesophageal Junction
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00054457
- Testing
- capecitabine, docetaxel
- Where
- 28 sites in United States
- Volunteers
- 46 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Esophageal Squamous Cell Cancer, Elderly Patients
Sequential Paclitaxel Chemotherapy and Radiotherapy as 1st Line Treatment for Elderly Esophageal Squamous Cell Cancer
Elderly patients with metastatic esophageal squamous cell carcinomas have poor prognosis and majority of them were intolerable to combined chemotherapy in China.
- Trial name
- NCT02016287
- Testing
- Sequential chemotherapy （paclitaxel 80mg/m2 d1,d8) and radiotherapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shen Lin
Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma
The goal of this single-arm study is to explore the efficacy and safety of Adebrelimab in combination with Apatinib and Tegafur for the treatment of locally advanced or metastatic esophageal squamous cell carcinoma that has…
- Trial name
- NCT06339619
- Testing
- Adebrelimab, Apatinib, Tegafur
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Lymph Node Metastasis
Machine Learning to Predict Lymph Node Metastasis in T1 Esophageal Squamous Cell Carcinoma
Existing models do poorly when it comes to quantifying the risk of Lymph node metastases (LNM). This study generated elastic net regression (ELR), random forest (RF), extreme gradient boosting (XGB), and a combined (ensemble)…
- Trial name
- NCT06256185
- Testing
- esophagectomy
- Where
- China
- Volunteers
- 1,267 people
- Sponsor
- Shanghai Zhongshan Hospital
Esophageal Cancer
A Clinical Study Of Camrelizumab With Or Without Radiotherapy In The Treatment Of Esophageal Cancer
The purpose of this study is to observe and evaluate the efficacy and safety of Camrelizumab combined with or without radiotherapy for the treatment of recurrent or metastatic esophageal cancer that has progressed after…
- Trial name
- NCT04512417
- Testing
- Camrelizumab+Radiotherapy, Camrelizumab
- Where
- China
- Volunteers
- 63 people
- Sponsor
- Zhejiang Cancer Hospital
Esophagogastric Junction Adenocarcinoma, Gastric Cancer
AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer
Study Phase: 1b/2 Indication: Previously untreated subjects with unresectable locally advanced or metastatic gastric or esophagogastric junction adenocarcinoma.
- Conditions
- Esophagogastric Junction Adenocarcinoma, Gastric Cancer, Esophageal Cancer
- Trial name
- NCT00719550
- Testing
- Capecitabine, Epirubicin, AMG 102
- Volunteers
- 130 people
- Sponsor
- Amgen
Melanoma, Non-small Cell Lung Cancer
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
This is a study to determine the maximum tolerated dose (MTD) for CDX-1140 (CD40 antibody), either alone or in combination with CDX-301 (FLT3L), pembrolizumab, or chemotherapy and to further evaluate its tolerability and efficacy…
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer
- Trial name
- NCT03329950
- Testing
- CDX-1140, CDX-301, pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 132 people
- Sponsor
- Celldex Therapeutics
Esophageal Cancer
Utidelone and Anlotinib in Advanced Recurrent Metastatic Esophageal Cancer
The goal of this clinical trial is to evaluate the safety, tolerance and efficacy of Utidelone combined with Anlotinib in patients with Advanced or Recurrent Esophageal Carcinoma who failed Standard first line therapy.
- Trial name
- NCT05866510
- Testing
- Utidelone and anlotinib
- Where
- 3 sites in China
- Volunteers
- 47 people
- Sponsor
- Peking University